Conformis Reports Preliminary Third Quarter Revenue Results
Expected Q3 Summary:
- Total revenue of approximately
$16.1 million, down 7% year-over-year on a reported and constant currency basis
- Royalty revenue of
- Product revenue of approximately
$16.0 million, down 7% year-over-year on a reported and constant currency basis
U.S.product revenue of approximately $14.1 million, down 7% year-over-year on a reported basis
- Rest of world product revenue of approximately
$1.8 million, down 7% year-over-year on a reported basis and 10% on a constant currency basis
- Hip revenue of approximately
$0.9 million, an increase of 122% year-over-year on a reported basis.
“In the quarter, we were pleased to see a continued resumption of elective primary joint replacement surgery,” said
- Protect our employees and their families
- Protect our production capability
- Protect and support our patients and customers
I am pleased that we have been successful thus far in matching commercial operations to customer requirements, maintaining R&D to keep our new product pipeline moving and appropriately managing cost and capitalizing the company.”
Third Quarter Earnings Call Announcement
To attend by telephone, please use the information below for dial-in access. When prompted on dial-in, please utilize conference ID: 3477925.
Participant conference numbers: (877) 809-6331 (
Please dial in at least 10 minutes before the call to ensure timely participation.
The webcast will be hosted by
The online archive of the webcast will be available on the Company’s website at ir.conformis.com for 30 days.
These preliminary results are being provided in advance of the Company’s
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release about our future expectations, plans and prospects, including statements about the anticipated impact of the novel coronavirus (COVID-19) pandemic and the actions we are taking and planning in response, the anticipated timing of our product launches, the extent to which restrictions on elective surgeries will continue to be relaxed and demand for procedures will increase, our ability to satisfy quarterly financial covenants, and our financial position and results, total revenue, product revenue, gross margin, operations and growth, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual financial results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to COVID-19 and the response to the pandemic; whether our cash resources will be sufficient to fund our continuing operations for the periods anticipated; risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the
CONTACT: Investor Relations firstname.lastname@example.org (781) 374-5598
Source: Conformis, Inc.